# GEM-KyCyDex (NCT03336073)

> Carfilzomib, Cyclophosphamide, Dexamethasone in Multiple Myeloma

No report yet. It can be ordered.

- Drugs tested: carfilzomib plus cyclophosphamide plus dexamethasone
- Indication: relapsed/refractory multiple myeloma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03336073
- Phase: PHASE2
- Status: UNKNOWN
- Sponsor: PETHEMA Foundation
- Conditions: Multiple Myeloma
- Interventions: Carfilzomib; Dexamethasone; cyclophosphamide
- Enrollment: 199
- Primary outcome: Progression free survival (PFS)

## Indexed commentary on GEM-KyCyDex so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=gem-kycydex-nct03336073